PYXS

1.8107.74%
DS

Darren S. Cline

Independent Director

Mr. Darren S. Cline, M.B.A. is Chief Commercial Officer of Xenon Pharmaceuticals Inc. from June 2025. Mr. Cline serves as Director of IPI Legacy Liquidation Co (formerly known as Impel Pharmaceuticals Inc.) since April 12, 2023. He serves as Director at Pliant Therapeutics, Inc. since March 2023. From March 2022 to March 2023, Mr. Cline served as Chief Executive Officer and President of Epygenix Therapeutics. From October 2010 to March 2019, Mr. Cline served in various roles at Seagen Inc. (formerly Seattle Genetics, Inc.), including as its Executive Vice President, Commercial, Senior Vice-President, Commercial and Vice President, Managed Markets, where he oversaw all marketing, sales and managed markets. He has been Independent Director of Pyxis Oncology, Inc. since September 2021. He was U.S. Chief Commercial Officer at GW Pharmaceuticals plc since April 22, 2019 to December 2021. He served as an Executive Vice President of Commercial at Seattle Genetics, Inc. since February 2016 until 2019 and served as its Senior Vice President of Commercial from February 2015 to February 2016. He oversaw all marketing, sales and managed markets at Seattle Genetics. Mr. Cline served as Vice President of Marketing, Managed Markets and Reimbursement at Seattle Genetics Inc. He is an accomplished biopharmaceutical executive with commercial experience, including hematology and oncology, orphan and ultra-orphan arenas. He served as Vice President of Managed Markets at Seattle Genetics Inc. since November 30, 2010. He served as Director of Stemline Therapeutics, Inc. since April 2018 until June 10, 2020. He served as Vice President of Managed Care and Market Access at InterMune Inc. since November 2009 and was responsible for obtaining managed markets access and coverage for the anticipated launch of pirfenidone. He was directly involved in the commercial build out for the launch of ADCETRIS and he played an integral role driving ADCETRIS. Mr. Cline has held senior sales, marketing and managed care roles at Schering-Plough, Amgen, InterMune. Mr. Cline was at Alexion Pharmaceuticals, where he was part of the initial commercial leadership team for the Soliris launch from October 2006 to October 2009. While at Amgen, he led a managed care team during the launches of Aranesp and Neulasta and was the Reimbursement and Access Marketing Director for Enbrel. Mr. Cline received a Bachelor's of Science degree in Marketing from San Diego State University and an M.B.A. from Pepperdine University in Malibu, CA.

Positions